UBS Maintains a 'Neutral' on Bristol-Myers Squibb Co. (BMY); Brivanib Misses in HCC

Article Stock Quotes (1) Comments (0)

UBS maintains a 'Neutral' on Bristol-Myers Squibb Co. (NYSE: BMY) price target of $36.00

Analyst, Marc Goodman, takes note of last night's press release where BMY reported the result of the phase III BRISK-FL clinical trial of the investigational agent brivanib versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC; liver cancer). The study did not meet its primary overall survival objective based upon a non-inferiority statistical design.

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $36.15 yesterday, with a 52 week range of $25.69-$36.34.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
• UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
• Pandora (P) Posts 'Strong Quarter' - Needham & Company

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

UBS

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?